[{"id":"d4594130-d033-44b6-a56a-f74eead9a72a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03083743","created_at":"2021-01-18T15:11:28.965Z","updated_at":"2024-07-02T16:37:24.299Z","phase":"Phase 3","brief_title":"A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection","source_id_and_acronym":"NCT03083743","lead_sponsor":"Shanghai Gebaide Biotechnology Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dulanermin (AMG 951)"],"overall_status":"Unknown status","enrollment":" Enrollment 417","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2017-03-20"}]